Modality
Vaccine
MOA
PD-L1i
Target
USP1
Pathway
Complement
Asthma
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Sep 2030
Phase 2Current
NCT07592451
876 pts·Asthma
2018-02→2030-09·Completed
NCT06421123
1,183 pts·Asthma
2020-02→TBD·Terminated
2,059 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-093mo agoFast Track· Asthma
2030-09-274.5y awayPh3 Readout· Asthma
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Complet…
P2/3
Termina…
Catalysts
Fast Track
2026-01-09 · 3mo ago
Asthma
Ph3 Readout
2030-09-27 · 4.5y away
Asthma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07592451 | Phase 2/3 | Asthma | Completed | 876 | SRI-4 |
| NCT06421123 | Phase 2/3 | Asthma | Terminated | 1183 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| 207-5197 | Samsung Biologics | Approved | BET |